Coordinating Leniency Across Germany, the EU and the US (2026): a Practical Guide for Multinational Companies

Cross-border leniency Germany strategy has become one of the most time-sensitive decisions a multinational can face in 2026, as cartel enforcers in Germany, the European Union and the United States coordinate investigations more closely than ever before. When conduct touches several markets, a leniency application filed in one jurisdiction rarely stands alone; the timing, content and confidentiality handling of each filing ripple across every other forum. This practical guide sets out a jurisdiction-by-jurisdiction playbook for in-house counsel, general counsel and external antitrust advisers who must decide whether and how to seek immunity or fine reductions from the Bundeskartellamt, the European Commission and the US Department of Justice simultaneously.

It covers marker strategy, the content of each application, confidentiality and privilege, and the interaction with follow-on private damages litigation.

Executive summary

This article distils the operational steps required to coordinate a cross-border leniency Germany application with parallel filings in the EU and the US. The core message is that leniency programmes run on similar principles but diverge sharply on criminal exposure, marker mechanics and the disclosure of corporate statements in civil litigation.

• Who this is for. General counsel, in-house antitrust teams and external counsel managing cartel exposure that spans the Bundeskartellamt, the European Commission and the DOJ.
• Act on timing first. Leniency is a race to be first. Secure a marker in each relevant jurisdiction before a competitor does, then build the evidentiary file.
• Criminal exposure changes the calculus. US antitrust violations carry criminal liability under the Sherman Act, so DOJ sequencing deserves particular weight.
• Confidentiality is not uniform. The protections afforded to leniency statements differ across regimes, with direct consequences for private damages claims.
• Govern the decision internally. Senior management and the GC must sign off against a structured risk matrix before any filing is made.

Why cross-border leniency decisions are urgent in 2026

The economics of leniency reward speed, and 2026 has raised the stakes. Enforcement agencies increasingly launch parallel probes, exchange information through established cooperation frameworks, and conduct coordinated inspections. A company that learns of potential cartel conduct can no longer treat each jurisdiction as a separate, sequential problem. A delay in one forum can forfeit the first-mover advantage in all of them, because the same whistleblower, the same employee or the same document trail may surface simultaneously before several authorities.

2026 enforcement landscape: Bundeskartellamt, EC, DOJ coordination

Within the European Union, the Commission and national competition authorities such as the Bundeskartellamt operate inside the European Competition Network, which provides a framework for allocating cases and sharing information between enforcers. Council Regulation (EC) No 1/2003 underpins this cooperation, giving the Commission investigative powers and establishing how authorities work together on conduct that affects trade between Member States. Across the Atlantic, the DOJ Antitrust Division pursues criminal cartel enforcement and routinely coordinates timing of its investigative steps with foreign counterparts. For any company weighing a cross-border leniency Germany filing, the practical reality is that regulators communicate with one another, and the window to self-report can close quickly.

Commercial stakes: fines, criminal exposure (US) and private damages

The consequences of cartel conduct are cumulative. In Germany, the Gesetz gegen Wettbewerbsbeschränkungen (GWB) establishes the statutory basis for administrative fines and the procedural framework the Bundeskartellamt applies. At EU level, the Commission can impose substantial fines for infringements of Article 101 TFEU. In the United States, the Sherman Act renders cartel conduct a criminal offence, exposing both corporations and individuals to prosecution. Layered on top of all three regimes is the growing risk of follow-on private damages litigation, in which injured customers pursue compensation. A well-coordinated cross-border leniency Germany strategy aims to reduce or eliminate fines while managing the downstream civil and criminal exposure that a self-report inevitably triggers.

Can you obtain leniency in Germany and the US for the same conduct?

Yes. A company can seek and obtain leniency in Germany, the European Union and the United States for the same underlying cartel conduct. Leniency programmes are not mutually exclusive, and multinational applicants routinely pursue parallel filings. What they are not is interchangeable: each authority runs its own programme with its own eligibility criteria, its own marker practice and its own cooperation obligations. Meeting the requirements in one forum does not guarantee qualification in another, and the information disclosed to satisfy one authority must be reconciled with what is disclosed to the others.

The practical limit is that full immunity is generally available only to the first qualifying applicant. If a competitor reaches the DOJ, the Bundeskartellamt or the Commission first, the slot for full immunity may already be taken, leaving only the prospect of a reduction. This is why a cross-border leniency Germany plan must treat each jurisdiction as a distinct race while coordinating the overall strategy centrally.

Immunity vs reduction: EC/Bundeskartellamt vs DOJ models

Under the European Commission’s leniency framework, the first undertaking to provide evidence that enables the Commission to find an infringement (or to carry out a targeted inspection) can obtain full immunity from fines; later cooperators may receive reductions on a sliding scale. The Bundeskartellamt operates an analogous system of immunity for the first applicant and reductions for subsequent ones, grounded in the enforcement architecture of the GWB, which since the 2021 GWB amendment incorporates the leniency programme into the statute itself.

The DOJ’s Leniency Program grants conditional leniency to the first corporate applicant that meets the Antitrust Division’s criteria, and crucially that leniency can extend to protection from criminal prosecution for the company and cooperating individuals, a dimension absent from the administrative German and EU regimes.

Timing, evidence and cooperation obligations that may differ

Although all three programmes demand full, continuing and genuine cooperation, the triggering conditions and evidentiary thresholds vary. The DOJ expects prompt and candid disclosure and ongoing cooperation throughout the investigation and any prosecution. The Commission and the Bundeskartellamt similarly require applicants to end their participation in the cartel, cooperate throughout, and refrain from destroying evidence. In a hypothetical but illustrative sequence, a company discovers suspect conduct through an internal audit, secures a DOJ marker to protect against criminal exposure, obtains an EC marker within days, and files a parallel Bundeskartellamt application, all before external counsel assembles the detailed evidentiary submission each authority ultimately requires. Coordinating these steps is the essence of a cross-border leniency Germany engagement.

Marker strategy, who to notify first, and why

The single most consequential decision in a multi-jurisdictional self-report is the order in which you approach the authorities. A marker reserves your place in the queue while you investigate and prepare a full submission. Because leniency rewards the first qualifying applicant, the marker is the instrument that locks in priority before the evidence is fully marshalled. A disciplined marker strategy balances the strength of the available evidence, the location of the conduct and documents, the risk of criminal referrals, and the confidentiality consequences of each disclosure.

The general principle is to prioritise the jurisdiction where the exposure is greatest and the forfeiture of first-mover status would be most damaging. In many cross-border leniency Germany matters involving US commerce, that points toward securing the DOJ marker early, because criminal liability for the corporation and for individual executives is often the most severe and least reversible consequence. At the same time, EU-level and German markers must follow quickly, because information can move between enforcers and a competitor’s filing in one forum can prompt action in another.

Marker mechanics: how markers work in Germany, the EU and the US

Across the three systems, a marker performs the same function, it preserves the applicant’s position in the leniency queue while the full application is prepared, but the mechanics differ. The Bundeskartellamt accepts leniency applications and permits applicants to secure their place with an initial marker while gathering the evidence required to perfect the application, as set out in its published leniency guidance. The European Commission similarly allows applicants to request a marker, after which the applicant must complete its submission within a period set by the Commission. The DOJ operates its own marker procedure, through which the Antitrust Division confirms an applicant’s place in line pending the provision of full information.

In every case, the marker is conditional: it protects priority only if the applicant then delivers the substantive cooperation the programme demands.

Priority factors: jurisdictional exposure, evidence location and potential criminal referrals

Deciding the sequence requires weighing several factors together:

• Jurisdictional exposure. Where is the conduct’s commercial and legal footprint heaviest? The jurisdiction with the largest potential fines or the most serious liability generally warrants early action.
• Criminal risk. Because the Sherman Act criminalises cartel conduct, the prospect of prosecution of the company or its employees in the United States typically elevates the DOJ in the priority order.
• Evidence location. Where documents, custodians and communications sit affects which authority can most readily act and which filing can be perfected fastest.
• Information sharing. Because enforcers within the European Competition Network and across borders exchange information, a filing in one forum may accelerate scrutiny in another, so markers should be sequenced tightly rather than spread over weeks.
• Confidentiality consequences. The downstream disclosure risk of a corporate statement varies by regime and should inform not just whether to file but how to frame each submission.

Practical timeline template and redlines for internal approval

A workable cross-border leniency Germany timeline compresses the critical early steps into a matter of days. In outline: day zero, identify the conduct and convene the response team; secure privileged advice and freeze document destruction; obtain the first marker in the highest-risk jurisdiction; obtain parallel markers in the remaining forums; then build and file the substantive applications within each authority’s deadline. Internal approval redlines, the points at which senior management and the GC must formally authorise action, should be embedded in the timeline so that no marker is sought and no statement is made without documented sign-off. A marker template and internal approval checklist support this process and are available on request.

What to include in each leniency application, Bundeskartellamt vs European Commission vs DOJ

While the three programmes share a common purpose, the content and form of a compliant application differ. The overarching requirement in each case is a detailed, truthful and corroborated account of the cartel, the participants, the duration and the affected markets, accompanied by supporting evidence. The sections below set out what each authority expects, and the comparison table later in this guide consolidates these into a side-by-side checklist for a cross-border leniency Germany filing.

Bundeskartellamt application specifics

An application to the Bundeskartellamt must describe the cartel conduct in sufficient detail to enable the authority to establish the infringement, identify the undertakings involved, and set out the applicant’s own role. The applicant must end its participation in the cartel, cooperate fully and continuously, and preserve rather than destroy relevant evidence. The statutory framework governing fines, procedure and the leniency programme sits within the GWB, and the Bundeskartellamt’s published guidance explains how applications are made, how markers reserve priority, and how the authority treats the information it receives. Applicants should be ready to produce internal documents, correspondence and witness accounts that corroborate the narrative, and should structure the submission to meet the authority’s expectations on completeness.

European Commission application specifics

The European Commission’s leniency notice sets out the criteria for immunity and for reductions, and the elements an application must contain. To qualify for immunity, the applicant must be the first to submit information and evidence that enables the Commission either to carry out a targeted inspection or to find an infringement of Article 101 TFEU. The submission should include a detailed description of the alleged cartel, its aims, operation, products, geographic scope and duration, together with the identities of the participating undertakings and individuals, and all evidence in the applicant’s possession or control.

As with the German regime, the applicant must cooperate genuinely, fully and on a continuous basis, must terminate its involvement, and must not have destroyed evidence or disclosed its application in a way that jeopardises the investigation.

DOJ application specifics

The DOJ Antitrust Division grants conditional leniency to the first qualifying corporate applicant that reports cartel conduct and satisfies the programme’s requirements. The applicant must take prompt and effective action to terminate its participation, report candidly with complete and truthful disclosure, provide ongoing and full cooperation, make restitution where appropriate, and not have coerced others to participate. Because US antitrust conduct carries criminal exposure under the Sherman Act, the DOJ application is framed against the backdrop of potential prosecution, and the conditional leniency secured can protect the company, and, where applicable, cooperating individuals, from criminal charges provided the conditions are met and maintained throughout.

Confidentiality, privilege and evidence handling in cross-border leniency Germany matters

Confidentiality is where a cross-border leniency Germany strategy most often succeeds or fails. The protections afforded to leniency statements and to privileged internal materials are not harmonised across jurisdictions, and a disclosure that is protected in one forum may be discoverable in another. Managing this requires careful handling of documents from the first day, including a rigorous privilege log and a clear separation between the oral and written components of each submission.

German rules and Bundeskartellamt practice on confidentiality

The Bundeskartellamt’s leniency guidance addresses how the authority treats the confidentiality of applications and the business secrets contained in them. Applicants should understand which parts of their submission may be protected and which may become accessible, particularly in the context of access-to-file and subsequent civil proceedings. Because the statutory enforcement framework rests on the GWB, the protection of sensitive commercial information and the handling of leniency statements are governed by the interplay of that statute and the authority’s practice. Applicants frequently rely on oral statements where available to limit the creation of discoverable written records, and structure their disclosures accordingly.

EC approach to confidentiality and business secrets

The European Commission’s leniency framework likewise recognises the need to protect corporate statements and business secrets, reflecting the tension between effective enforcement and the risk that leniency disclosures could be weaponised in follow-on litigation. The EU Antitrust Damages Directive (2014/104/EU), as transposed into German law through the GWB, provides specific protection for leniency corporate statements against disclosure in damages proceedings. Applicants should pay close attention to how the Commission handles access to the file, the treatment of leniency corporate statements, and the redaction of confidential information. The use of oral submissions is a recognised mechanism for limiting the written footprint of sensitive admissions, and counsel should plan each disclosure with the eventual access-to-file consequences in mind.

DOJ treatment and plea/cooperation implications

In the United States, the DOJ’s handling of information provided under the Leniency Program is bound up with the criminal process and the cooperation that program participation entails. The confidentiality of submissions, the sequencing of disclosure, and the implications for any plea or cooperation agreement all need to be managed so that the company preserves its leniency protection without creating unnecessary exposure in parallel civil litigation.

A practical confidentiality checklist for any cross-border leniency Germany engagement should include: implementing an immediate litigation hold; maintaining a detailed privilege log; separating privileged advice from factual investigative material; preferring oral submissions where the relevant authority permits them; and coordinating the content of parallel filings so that an admission made in one forum does not undermine the applicant’s position in another.

Interaction with follow-on private damages litigation

Securing leniency reduces or eliminates regulatory fines, but it does not extinguish civil liability. Across the EU, Germany and the United States, customers and competitors harmed by a cartel can pursue damages, and a self-report can hand would-be claimants a roadmap. The central risk is that the very cooperation that earns leniency generates documents and admissions that private litigants seek to obtain. Managing that risk is an integral part of any cross-border leniency Germany plan.

Germany and EU private damages regimes

Private enforcement has grown substantially within the EU and Germany, with injured parties entitled to seek compensation for harm caused by competition law infringements. The EU Antitrust Damages Directive and its transposition into the GWB established a framework in which, among other things, a final infringement decision by a competition authority is binding in subsequent damages proceedings, while leniency corporate statements are protected from disclosure. Regulatory evidence can nonetheless become relevant to these claims, and the European Competition Network framework governs how information flows between the Commission and national authorities such as the Bundeskartellamt.

Applicants must therefore consider how the material in their leniency file could feature in subsequent damages proceedings, and plan their submissions, and their use of oral statements, to limit avoidable exposure.

US private antitrust litigation and criminal cooperation consequences

In the United States, private antitrust litigation is a well-established and often aggressive feature of the enforcement landscape, and plaintiffs can in principle pursue treble damages. A successful DOJ leniency applicant may, under the Antitrust Criminal Penalty Enhancement and Reform Act (ACPERA) and its subsequent reauthorisation, benefit from a limitation of its civil damages exposure to single damages for the conduct covered, provided it satisfies the statutory cooperation conditions with claimants. Participation in the DOJ Leniency Program thus carries cooperation consequences that interact with civil exposure, and the criminal dimension under the Sherman Act adds a layer absent from the administrative European and German regimes.

A leniency applicant must weigh the benefit of criminal protection against the possibility that its cooperation becomes a foundation for civil claims, and should coordinate its US position with its European filings.

Practical mitigation tactics

Mitigation centres on disclosure control, the strategic use of settlements and releases, and careful management of what is reduced to writing. Early, coordinated planning across all forums is the most effective protection against follow-on exposure.

Tactical playbook: step-by-step checklist for in-house counsel

The following ten-step checklist translates the strategy above into an operational sequence for in-house teams managing a cross-border leniency Germany situation:

1. Identify and preliminarily assess the suspected conduct through a privileged internal review.
2. Convene a response team and engage external antitrust counsel immediately.
3. Implement a litigation hold and suspend any document destruction.
4. Map the jurisdictional exposure, evidence location and criminal risk.
5. Decide the marker priority order against the risk matrix.
6. Secure the first marker in the highest-risk jurisdiction.
7. Obtain parallel markers in the remaining forums without delay.
8. Build and file the substantive applications within each authority’s deadline.
9. Maintain full, genuine and continuous cooperation across all forums.
10. Monitor downstream civil exposure and manage confidentiality throughout.

Roles and approvals: who signs off internally?

No marker should be filed and no statement made without documented authorisation from senior management and the general counsel. The decision to self-report is typically a board-level matter with significant financial, reputational and personal consequences, and the approval chain must be recorded. A structured risk matrix should accompany the sign-off so that the decision rests on a clear, defensible assessment of exposure across Germany, the EU and the US.

Communication with counsel and employees

Internal communications must be managed carefully to preserve privilege and to ensure consistency across jurisdictions. It is worth noting that the scope of legal privilege differs: in-house counsel communications are generally not protected under EU competition procedure, whereas US practice is broader. Employees who may be witnesses require guidance on their obligations, and all communication should be channelled through counsel to protect the integrity of the cooperation and to avoid inadvertent waiver of privilege.

Post-leniency reporting and monitoring

Leniency is conditional and ongoing. After the applications are filed, the company must continue to cooperate, respond to information requests, and monitor developments in every forum. Compliance with the conditions must be tracked so that the protection secured is not forfeited through a lapse in cooperation.

Comparison table, Bundeskartellamt vs European Commission vs DOJ

The table below consolidates the key differences that shape a cross-border leniency Germany decision. It is intended as a tactical reference for sequencing markers, framing applications and managing confidentiality across the three regimes.

Practical templates and annexes

To operationalise a cross-border leniency Germany decision, three supporting assets are particularly valuable: a marker template that structures the initial request to each authority; an internal approval checklist that records the required sign-offs and risk assessment; and an evidence map template that catalogues documents and custodians by jurisdiction. These assets help compress the critical early days and ensure that nothing material is overlooked under time pressure. They are available on request through our Competition counsel contact channels. For broader context, see our Germany, Competition practice area and the GLE lawyer directory, Competition lawyers in Germany.

Conclusion and next steps

A successful cross-border leniency Germany strategy turns on three disciplines: securing markers in the right order before competitors act, tailoring each application to the Bundeskartellamt, European Commission and DOJ requirements, and controlling confidentiality to limit follow-on damages exposure. Because enforcers coordinate and information moves quickly in 2026, the window to act is often short and the margin for error is narrow. Companies facing potential cartel exposure should convene counsel promptly, map their exposure across all relevant forums, and work from a documented playbook. To discuss a specific cross-border leniency Germany matter, contact a Competition lawyer in Germany through Global Law Experts.

Sources

1. Bundeskartellamt, Leniency / Immunity information and guidance
2. Gesetz gegen Wettbewerbsbeschränkungen (GWB), consolidated text
3. European Commission, Antitrust leniency information and Notice
4. Council Regulation (EC) No 1/2003, EUR-Lex
5. Directive 2014/104/EU on antitrust damages actions, EUR-Lex
6. U.S. Department of Justice, Antitrust Division, Leniency Program
7. U.S. Code, Sherman Act (15 U.S.C. §1), Legal Information Institute
8. European Competition Network (ECN), cooperation framework